1
|
Li J, Mei J, Yu J, Chen X, Zhu J, Ye J, Zhang D, Cheng D, Chen X. Characteristics of molecular epidemiology and transmitted drug resistance among newly diagnosed HIV-1 infections in Lishui, China from 2020 to 2023. Virol J 2025; 22:111. [PMID: 40253369 PMCID: PMC12008846 DOI: 10.1186/s12985-025-02734-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2025] [Accepted: 04/10/2025] [Indexed: 04/21/2025] Open
Abstract
BACKGROUND Transmitted drug resistance (TDR) is becoming an obstacle to the success of antiretroviral therapy (ART) as the HIV epidemic continues to spread. This study aimed to investigate the characteristics of TDR and the molecular epidemiology of ART-naive HIV-1 infections in Lishui. METHODS A total of 481 plasma samples were collected from ART-naive HIV-1 infections in Lishui between 2020 and 2023. The sequences acquired from infections were used to analyze the characteristics of genotype, TDR, and molecular transmission network. RESULTS This study discovered that the three most prevalent subtypes among the 455 sequences successfully obtained from infections in Lishui were CRF08_BC (35.8%), CRF07_BC (26.4%), and CRF01_AE (25.9%). The overall prevalence of TDR was 12.1%, and the K103N (2.4%) was the most frequent mutation. Multivariate analysis showed that CRF08_BC (OR = 5.401, P < 0.001) and CD4+ cell concentration of 200-499 cells/µL (OR = 1.684, P = 0.030) were associated with a higher risk of entering the molecular transmission network and clustering, whereas the current address in other cities (OR = 0.328, P = 0.004), junior middle school (OR = 0.472, P = 0.006), and junior college or above (OR = 0.387, P = 0.045) were associated with a lower risk of clustering. CONCLUSIONS This study revealed that the prevalence of TDR was at an intermediate level of drug resistance, and high levels of resistance were predominantly concentrated in efavirenz (EFV) and nevirapine (NVP) among the NNRTIs. Middle-aged and older infections represented a significant proportion of the molecular transmission network. This suggests that HIV surveillance and targeted prevention and treatment interventions are essential to reduce the risk of HIV transmission.
Collapse
Affiliation(s)
- Jinkai Li
- School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, 310053, China
- Lishui Center for Disease Control and Prevention, Lishui, 323000, China
| | - Jianhua Mei
- Lishui Center for Disease Control and Prevention, Lishui, 323000, China
| | - Jie Yu
- Lishui Center for Disease Control and Prevention, Lishui, 323000, China
| | - Xiaolei Chen
- Lishui Center for Disease Control and Prevention, Lishui, 323000, China
| | - Jianliang Zhu
- Lishui Center for Disease Control and Prevention, Lishui, 323000, China
| | - Jiaji Ye
- School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Deyong Zhang
- Lishui Center for Disease Control and Prevention, Lishui, 323000, China.
| | - Dongqing Cheng
- School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
| | - Xiuying Chen
- Lishui Center for Disease Control and Prevention, Lishui, 323000, China.
| |
Collapse
|
2
|
Zhang L, Feng Y, Shen K, Wang L, Wang Y, Lu J, Gao H, Li H, Han J, Li L, Dai E. Near-Full-Length Genomic Characterization of Two Novel HIV-1 Unique Recombinants (CRF01_AE/CRF07_BC) and (CRF01_AE/CRF68_01B) in Shijiazhuang, Hebei Province, China. AIDS Res Hum Retroviruses 2025. [PMID: 39964836 DOI: 10.1089/aid.2024.0114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2025] Open
Abstract
Heterosexual transmission (HETE) represents the predominant method of transmission for the human immunodeficiency virus type 1 (HIV-1) in Shijiazhuang, Hebei Province, China. The number of circulating recombinant forms (CRFs) and unique recombinant forms (URFs) continues to increase in this region. In the present study, two novel URFs (TFH010919 and TFH010944) were identified, both derived from HETEs in the Shijiazhuang area. The phylogenetic and recombination breakpoint analyses conducted on the near-full-length genomes of the two novel URFs revealed that the CRF01_AE strains serve as the predominant backbones for both TFH010919 and TFH010944. TFH010919 is a second-generation recombinant form composed of CRF01_AE and CRF07_BC, whereas TFH010944 is formed by the combination of CRF01_AE and CRF68_01B. This finding indicates that HIV-1 prevalence among HETEs remains a significant concern, driven by complex sexual networks that facilitate the spread of diverse recombinant strains, providing more opportunities for the recombination of viruses. The emergence of these new URFs revealed the ongoing evolution of HIV-1 and underscores the critical need for continuous monitoring of viral diversity in Hebei Province and surrounding regions to control HIV-1 transmission within the vulnerable population and beyond.
Collapse
Affiliation(s)
- Lixuan Zhang
- Department of Clinical Laboratory Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, China
- Department of AIDS Research, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China
| | - Yuxin Feng
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China
| | - Kuiling Shen
- Department of AIDS Research, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
- School of Public Health, Hebei Medical University, Shijiazhuang, China
| | - Lijing Wang
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China
| | - Yuling Wang
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China
| | - Jianhua Lu
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China
| | - Huixia Gao
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China
| | - Hanping Li
- Department of AIDS Research, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Jingwan Han
- Department of AIDS Research, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Lin Li
- Department of AIDS Research, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China
| | - Erhei Dai
- Department of Clinical Laboratory Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, China
- Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China
| |
Collapse
|
3
|
Ye J, Dong Y, Lan Y, Chen J, Zhou Y, Liu J, Yuan D, Lu X, Guo W, Zheng M, Yang H, Song X, Liu C, Zhou Q, Zheng C, Guo Q, Yang X, Zhang L, Ge Z, Liu L, Yu F, Han Y, Huang H, Hao M, Ruan Y, Wu J, Li J, Chen Q, Ning Z, Ling X, Zhou C, Liu X, Bai J, Gao Y, Tong X, Zhou K, Mei F, Yang Z, Wang A, Wei W, Qiao R, Luo X, Huang X, Wang J, Shen X, Hu F, Zhang L, Tan W, Fan J, Tu A, Yu G, Fang Y, He S, Chen X, Wu D, Zhang X, Xin R, He X, Ren X, Xu C, Sun Y, Li Y, Liu G, Li X, Duan J, Huang T, Shao Y, Feng Y, Pan Q, Su B, Jiang T, Zhao H, Zhang T, Chen F, Hu B, Wang H, Zhao J, Cai K, Sun W, Gao B, Ning T, Liang S, Huo Y, Fu G, Li F, Lin Y, Xing H, Lu H. Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023. J Infect Dis 2024; 230:1410-1421. [PMID: 39189826 DOI: 10.1093/infdis/jiae303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Accepted: 06/04/2024] [Indexed: 08/28/2024] Open
Abstract
BACKGROUND National treatment guidelines of China evolving necessitates population-level surveillance of transmitted drug resistance (TDR) to inform or update HIV treatment strategies. METHODS We analyzed the demographic, clinical, and virologic data obtained from people with HIV (PWH) residing in 31 provinces of China who were newly diagnosed between 2018 and 2023. Evidence of TDR was defined by the World Health Organization list for surveillance of drug resistance mutations. RESULTS Among the 22 124 PWH with protease and reverse transcriptase sequences, 965 (4.36%; 95% CI, 4.1-4.63) had at least 1 TDR mutation. The most frequent TDR mutations were nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.39%; 95% CI, 2.19%-2.59%), followed by nucleoside reverse transcriptase inhibitor mutations(1.35%; 95% CI, 1.2%-1.5%) and protease inhibitor mutations (1.12%; 95% CI, .98%-1.26%). The overall protease and reverse transcriptase TDR increased significantly from 4.05% (95% CI, 3.61%-4.52%) in 2018 to 5.39% (95% CI, 4.33%-6.57%) in 2023. A low level of integrase strand transfer inhibitor TDR was detected in 9 (0.21%; 95% CI, .1%-.38%) of 4205 PWH. CONCLUSIONS Presently, the continued use of NNRTI-based first-line antiretroviral therapy regimen for HIV treatment has been justified.
Collapse
Affiliation(s)
- Jingrong Ye
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Yuan Dong
- Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC, Shanghai
| | - Yun Lan
- Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou
| | - Jing Chen
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Ying Zhou
- Institute of AIDS/STD Control and Prevention, Jiangsu CDC, Nanjing
| | - Jinjin Liu
- Center for Translational Medicine, Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, The Sixth People's Hospital of Zhengzhou), Zhengzhou
| | - Dan Yuan
- Center for AIDS/STD Control and Prevention, Sichuan CDC, Chengdu
| | - Xinli Lu
- Department of AIDS Research, Hebei Key Laboratory of Pathogen and Epidemiology of Infectious Disease, Hebei CDC, Shijiazhuang
| | - Weigui Guo
- Institute of HIV/AIDS Prevention and Control, Beihai CDC, Beihai
| | - Minna Zheng
- Department of STDs/AIDS Control and Prevention, Tianjin CDC, Tianjin
| | - Hong Yang
- STD/AIDS Prevention and Control Institute, Inner Mongolia CDC (Inner Mongolia Academy of Preventive Medicine), Hohhot
| | - Xiao Song
- Institute for HIV/AIDS and STD Prevention and Control, Heilongjiang CDC, Harbin
| | | | - Quanhua Zhou
- Institute of Microbiology, Chongqing CDC, Chongqing
| | - Chenli Zheng
- Department of HIV/AIDS Control and Prevention, Shenzhen CDC, Shenzhen
| | - Qi Guo
- Virology Laboratory, Jilin CDC, Changchun
| | - Xiaohui Yang
- Institute for HIV/AIDS and STD Prevention and Control, Fuyang CDC, Fuyang
| | - Lincai Zhang
- Institute for HIV/AIDS and STD Prevention and Control, Gansu CDC, Lanzhou
| | - Zhangwen Ge
- Guizhou Provincial People's Hospital, Affiliated Hospital of Guizhou University, Guiyang
| | - Lifeng Liu
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing
| | - Fengting Yu
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing
| | - Yang Han
- Department of Infectious Disease, Peking Union Medical College Hospital, Beijing
| | - Huihuang Huang
- Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing
| | - Mingqiang Hao
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Yuhua Ruan
- Division of Virology and Immunology, State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Prevention and Control, China CDC, Beijing
| | - Jianjun Wu
- Institute for HIV/AIDS and STD Prevention and Control, Anhui CDC, Hefei
| | - Jianjun Li
- Institute of HIV/AIDS Prevention and Control, Guangxi CDC, Nanning
| | - Qiang Chen
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Zhen Ning
- Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC, Shanghai
| | - Xuemei Ling
- Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou
| | - Chang Zhou
- Center for AIDS/STD Control and Prevention, Sichuan CDC, Chengdu
| | - Xuangu Liu
- Institute of HIV/AIDS Prevention and Control, Beihai CDC, Beihai
| | - Jianyun Bai
- Department of STDs/AIDS Control and Prevention, Tianjin CDC, Tianjin
| | - Ya Gao
- STD/AIDS Prevention and Control Institute, Inner Mongolia CDC (Inner Mongolia Academy of Preventive Medicine), Hohhot
| | - Xue Tong
- Institute for HIV/AIDS and STD Prevention and Control, Heilongjiang CDC, Harbin
| | | | | | - Zhengrong Yang
- Department of HIV/AIDS Control and Prevention, Shenzhen CDC, Shenzhen
| | - Ao Wang
- Virology Laboratory, Jilin CDC, Changchun
| | - Wei Wei
- Institute for HIV/AIDS and STD Prevention and Control, Fuyang CDC, Fuyang
| | - Ruijuan Qiao
- Institute for HIV/AIDS and STD Prevention and Control, Gansu CDC, Lanzhou
| | - Xinhua Luo
- Guizhou Provincial People's Hospital, Affiliated Hospital of Guizhou University, Guiyang
| | - Xiaojie Huang
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing
| | - Juan Wang
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Xin Shen
- Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC, Shanghai
| | - Fengyu Hu
- Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou
| | - Linglin Zhang
- Center for AIDS/STD Control and Prevention, Sichuan CDC, Chengdu
| | - Wei Tan
- Department of HIV/AIDS Control and Prevention, Shenzhen CDC, Shenzhen
| | | | - Aixia Tu
- Institute for HIV/AIDS and STD Prevention and Control, Gansu CDC, Lanzhou
| | - Guolong Yu
- Institute of Pathogenic Microbiology, Guangdong CDC, Guangzhou
| | - Yong Fang
- Department of Laboratory, Meigu CDC, Meigu
| | - Shufang He
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Xin Chen
- Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC, Shanghai
| | - Donglin Wu
- Virology Laboratory, Jilin CDC, Changchun
| | - Xinhui Zhang
- Institute for Infectious Disease Prevention and Control, Guizhou CDC, Guiyang
| | - Ruolei Xin
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Xin He
- Department of Laboratory, Meigu CDC, Meigu
| | - Xianlong Ren
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Conghui Xu
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Yanming Sun
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Yang Li
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Guowu Liu
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Xiyao Li
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| | - Junyi Duan
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing
| | - Tao Huang
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing
| | - Yiming Shao
- Division of Virology and Immunology, State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Prevention and Control, China CDC, Beijing
| | - Yi Feng
- Division of Virology and Immunology, State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Prevention and Control, China CDC, Beijing
| | - Qichao Pan
- Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC, Shanghai
| | - Bin Su
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing
| | - Tianjun Jiang
- Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing
| | - Hongxin Zhao
- Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing
| | - Tong Zhang
- Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing
| | - Faqing Chen
- Institute for HIV/AIDS and STD Prevention and Control, Gansu CDC, Lanzhou
| | - Bing Hu
- Institute for HIV/AIDS and STD Prevention and Control, Fuyang CDC, Fuyang
| | - Hui Wang
- Virology Laboratory, Jilin CDC, Changchun
| | - Jin Zhao
- Department of HIV/AIDS Control and Prevention, Shenzhen CDC, Shenzhen
| | | | - Wei Sun
- Institute for HIV/AIDS and STD Prevention and Control, Heilongjiang CDC, Harbin
| | - Baicheng Gao
- STD/AIDS Prevention and Control Institute, Inner Mongolia CDC (Inner Mongolia Academy of Preventive Medicine), Hohhot
| | - Tielin Ning
- Department of STDs/AIDS Control and Prevention, Tianjin CDC, Tianjin
| | - Shu Liang
- Center for AIDS/STD Control and Prevention, Sichuan CDC, Chengdu
| | - Yuqi Huo
- Center for Translational Medicine, Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, The Sixth People's Hospital of Zhengzhou), Zhengzhou
| | - Gengfeng Fu
- Institute of AIDS/STD Control and Prevention, Jiangsu CDC, Nanjing
| | - Feng Li
- Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou
| | - Yi Lin
- Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC, Shanghai
- Shanghai Institutes of Preventive Medicine, Shanghai
- Shanghai Center for AIDS Research, Shanghai
| | - Hui Xing
- Division of Virology and Immunology, State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Prevention and Control, China CDC, Beijing
| | - Hongyan Lu
- Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC), Beijing Academy of Preventive Medicine, Beijing
| |
Collapse
|
4
|
Shi YZ, Huang HH, Wang XH, Song B, Jiang TJ, Yu MR, Wang ZR, Li RT, Jiao YM, Su X, Wang FS. Retrospective Study on Genetic Diversity and Drug Resistance among People Living with HIV at an AIDS Clinic in Beijing. Pharmaceuticals (Basel) 2024; 17:115. [PMID: 38256948 PMCID: PMC10819489 DOI: 10.3390/ph17010115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 01/03/2024] [Accepted: 01/10/2024] [Indexed: 01/24/2024] Open
Abstract
(1) Background: The objective of this study was to investigate the prevalence of genetic diversity and drug resistance mutations among people living with HIV (PLWH) attending clinics in Beijing. (2) Methods: A retrospective analysis was conducted on PLWH admitted to the Fifth Medical Center of People's Liberation Army (PLA) General Hospital between 1 March 2013 and 31 July 2020. The participants were analyzed for pretreatment drug resistance (PDR) and acquired drug resistance (ADR). Nested polymerase chain reaction (PCR) was utilized to amplify the pol gene from plasma RNA samples obtained from the participants. Genotypic and HIV drug resistance were determined using the Stanford University HIV Drug Resistance Database. Univariate and multifactorial logistic analyses were used to assess the risk factors for PDR. (3) Results: The overall prevalence rates of PDR and ADR were 12.9% and 27.8%, respectively. Individuals treated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) exhibited the highest prevalence of mutations. Specific mutation sites, such as V179D for NNRTIs and M184V and K65R for nucleoside reverse transcriptase inhibitors (NRTIs), were identified as prevalent mutations. Individuals treated with efavirenz (EFV) and nevirapine (NVP) were found to be susceptible to developing resistance. The multifactorial regression analyses indicated that the factors of circulating recombination form (CRF) genotype CRF07-BC and a high viral load were associated with an increased risk of PDR. CRF01-AE and CRF07-BC were the most prevalent HIV genotypes in our study. (4) Conclusions: The distribution of HIV genotypes in Beijing is complex. There is a need for baseline screening for HIV drug resistance among ART-naive individuals, as well as timely testing for drug resistance among ART-experienced individuals.
Collapse
Affiliation(s)
- Yan-Ze Shi
- Medical School of Chinese People’s Liberation Army (PLA), Beijing 100853, China; (Y.-Z.S.); (M.-R.Y.); (Z.-R.W.)
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Hui-Huang Huang
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Xin-Hua Wang
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Bing Song
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Tian-Jun Jiang
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Min-Rui Yu
- Medical School of Chinese People’s Liberation Army (PLA), Beijing 100853, China; (Y.-Z.S.); (M.-R.Y.); (Z.-R.W.)
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Ze-Rui Wang
- Medical School of Chinese People’s Liberation Army (PLA), Beijing 100853, China; (Y.-Z.S.); (M.-R.Y.); (Z.-R.W.)
- Department of Gastroenterology, First Medical Center of Chinese PLA General Hospital, Beijing 100036, China
| | - Rui-Ting Li
- State Key Laboratory of Pathogenand Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS), Beijing 100850, China;
| | - Yan-Mei Jiao
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Xin Su
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| | - Fu-Sheng Wang
- Medical School of Chinese People’s Liberation Army (PLA), Beijing 100853, China; (Y.-Z.S.); (M.-R.Y.); (Z.-R.W.)
- Department of Infectious Diseases, The Fifth Medical Centre of Chinese PLA General Hospital, National Clinical Research Centre for Infectious Diseases, Beijing 100853, China; (H.-H.H.); (X.-H.W.); (T.-J.J.)
| |
Collapse
|
5
|
Dai M, Li J, Li J, Lu H, Huang C, Lv S, Huang H, Xin R. Genetic characteristics of a novel HIV-1 recombinant lineage (CRF103_01B) and its prevalence in northern China. Virus Genes 2023:10.1007/s11262-023-01994-0. [PMID: 37079189 DOI: 10.1007/s11262-023-01994-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 04/07/2023] [Indexed: 04/21/2023]
Abstract
During the routine surveillance of HIV-1 pretreatment drug resistance in Beijing, five men who have sex with men (MSM) and a woman were observed to get infected by newly identified CRF103_01B strain. To elucidate the genetic characteristics, the near full-length genome (NFLG) was obtained. Phylogenetic inference indicated that CRF103_01B NFLG was composed of six mosaic segments. Segments IV and V of CRF103_01B were located among the clusters subtype B and CRF01_AE (group 5), respectively. The CRF103_01B strain was deduced to originate from Beijing MSM population around 2002.3-2006.4 and continued to spread among MSM population at a low level, then to the general population via heterosexual contact in northern China. Molecular epidemiology surveillance of CRF103_01B should be reinforced.
Collapse
Affiliation(s)
- Man Dai
- China Medical University, Shenyang, 110122, China
- Beijing Center for Disease Prevention and Control, Beijing, 100013, China
| | - Jia Li
- Beijing Center for Disease Prevention and Control, Beijing, 100013, China
| | - Jie Li
- Beijing Center for Disease Prevention and Control, Beijing, 100013, China
| | - Hongyan Lu
- Beijing Center for Disease Prevention and Control, Beijing, 100013, China
| | - Chun Huang
- Beijing Center for Disease Prevention and Control, Beijing, 100013, China
| | - Shiyun Lv
- Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China
| | - Huihuang Huang
- The Fifth Medical Center of PLA General Hospital, Beijing, 100039, China.
| | - Ruolei Xin
- Beijing Center for Disease Prevention and Control, Beijing, 100013, China.
| |
Collapse
|
6
|
Su Y, Qi M, Zhong M, Yu N, Chen C, Ye Z, Cheng C, Hu Z, Zhang H, Wei H. Prevalence of HIV Transmitted Drug Resistance in Nanjing from 2018 to 2021. Infect Drug Resist 2023; 16:735-745. [PMID: 36756611 PMCID: PMC9901445 DOI: 10.2147/idr.s391296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 12/16/2022] [Indexed: 02/05/2023] Open
Abstract
Background Transmitted drug resistance (TDR) is a major challenge in the clinical management of acquired immunodeficiency syndrome (AIDS). Therefore, this study aimed to investigate the epidemic characteristics of and risk factors for human immunodeficiency virus (HIV)-1 TDR in Nanjing from 2018 to 2021 to provide support for clinical management. Methods The HIV-1 Pol gene was amplified by nested reverse transcription polymerase chain reaction from venous blood of 1190 HIV-infected patients who did not receive antiviral therapy, and the amplified product was sequenced using an in-house sequencing method. The sequencing result was compared with the HIV drug resistance database from Stanford University to elucidate the rates of antiviral drug resistance and distribution of drug-resistant mutation sites. Factors associated with TDR were evaluated using a logistic regression model. Results Detection of drug resistance at the gene level was successful in 1138 of 1190 HIV-1-infected patients (95.6%), and the overall 4-year drug resistance rate was 8.2% (93/1138). The drug resistance rate was higher for non-nucleoside reverse transcriptase inhibitors (NNRTIs; 6.7%) than for nucleoside reverse transcriptase inhibitors (NRTIs; 2.5%) or protease inhibitors (PIs; 0.1%) (χ 2 = 83.907, P<0.0001). The most common NNRTI-related mutation was V179D/E followed by K103N. M184V was the dominant NRTI-associated mutation, and M46L/I was the most prevalent PI-associated mutation. A CD4+ T cell count of <50 cells/μL was significantly associated with an increased risk of TDR (OR=3.62, 95% CI: 1.38-9.51, P=0.009). Conclusion The prevalence of TDR in the city of Nanjing from 2018 to 2021 was at a moderate epidemic risk according to World Health Organization standards. Continuous monitoring of TDR can inform clinical diagnosis and treatment. Patients with advanced disease and a low CD4+ T lymphocyte count are more likely to have TDR in Nanjing.
Collapse
Affiliation(s)
- Yifan Su
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China
| | - Mingxue Qi
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China
| | - Mingli Zhong
- Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Nawei Yu
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China
| | - Chen Chen
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China
| | - Zi Ye
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China
| | - Cong Cheng
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China
| | - Zhiliang Hu
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China
| | - Hongying Zhang
- Nanjing Center for Disease Control and Prevention Affiliated with Nanjing Medical University, Nanjing, People’s Republic of China,Hongying Zhang, Email
| | - Hongxia Wei
- Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China,Correspondence: Hongxia Wei, Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003, People’s Republic of China, Email
| |
Collapse
|
7
|
Li QH, Wang JY, Liu SY, Zhang YQ, Li EL, Wang YR, Zhang SL, Zhao WB, Liu SL, Chen XH, Wang FX. Young MSM changed temporal HIV-1 epidemic pattern in Heilongjiang Province, China. Front Microbiol 2022; 13:1028383. [PMID: 36504809 PMCID: PMC9732660 DOI: 10.3389/fmicb.2022.1028383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 11/02/2022] [Indexed: 11/26/2022] Open
Abstract
Background Human immunodeficiency virus type 1 (HIV-1) epidemic in China is featured by geographical diversity of epidemic patterns. Understanding the characteristics of regional HIV-1 epidemic allows carrying out targeted prevention and controlling measures. This seven-year cross-sectional study was conducted in Heilongjiang, one province of Northeast China, where newly diagnosed infection is fast increasing yearly, but temporal HIV-1 epidemic trend is largely unknown. Methods Information of 1,006 newly diagnosed HIV-1-infected participants were collected before antiretroviral therapy during 2010-2016 in Heilongjiang province. HIV-1 genotype was identified based on the viral gag and env gene sequences. Recent infection was determined by Limiting-Antigen Avidity assays. Comparison analyses on the median ages, CD4 counts, proportions of stratified age groups and CD4 count groups, and rates of recent HIV-1 infection among different population and sampling times were performed to understand temporal HIV-1 epidemic features. Results Homosexual contact among men who have sex with men (MSM) was the main transmission route and CRF01_AE was the most dominant HIV-1 genotype. During 2010-2016, the HIV-1 epidemic showed three new changes: the median age continued to decline, the cases with a CD4 count more than 500 cells/μl (CD4hi cases) disproportionally expanded, and the recent HIV-1 infection rate steadily increased. MSM cases determined the temporal trend of HIV-1 epidemic here. Increase of young MSM cases (aged <30 years) made the main contribution to the younger age trend of MSM cases. These young MSM exhibited a higher median CD4 count, a higher proportion of CD4hi cases, and a higher rate of recent HIV-1 infection than cases aged 30 years and more. MSM infected by CRF01_AE virus mostly affected HIV-1 epidemic patterns among MSM population. Conclusion Young MSM have become a new hotspot and vulnerable group for HIV-1 transmission in Heilongjiang Province, Northeast China. The rapid increase in the number of young MSM cases, mainly those with CRF01_AE infection, changed temporal HIV-1 epidemic pattern here. Measures for prevention and control of HIV-1 infection among this population are urgently needed in the future.
Collapse
Affiliation(s)
- Qing-Hai Li
- Genomics Research Center, College of Pharmacy, Harbin Medical University, Harbin, China
| | - Jia-Ye Wang
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Si-Yu Liu
- Department of Infectious Diseases, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Yun-Qi Zhang
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - En-Long Li
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Yi-Ru Wang
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Shu-Lei Zhang
- Genomics Research Center, College of Pharmacy, Harbin Medical University, Harbin, China
| | - Wen-Bo Zhao
- Genomics Research Center, College of Pharmacy, Harbin Medical University, Harbin, China
| | - Shu-Lin Liu
- Genomics Research Center, College of Pharmacy, Harbin Medical University, Harbin, China,Shu-Lin Liu,
| | - Xiao-Hong Chen
- Department of Infectious Diseases, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China,Xiao-Hong Chen,
| | - Fu-Xiang Wang
- Department of Infectious Diseases, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China,Department of Infectious Diseases, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China,Department of Infectious Diseases, The Third People’s Hospital of Shenzhen, Shenzhen, China,*Correspondence: Fu-Xiang Wang,
| |
Collapse
|
8
|
Li Q, Yu F, Song C, Zhao H, Yan L, Xiao Q, Lao X, Yang S, Tang Y, Xiao J, Zhang F. A Concentration Method for HIV Drug Resistance Testing in Low-Level Viremia Samples. BIOMED RESEARCH INTERNATIONAL 2022; 2022:2100254. [PMID: 36467892 PMCID: PMC9711986 DOI: 10.1155/2022/2100254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 10/15/2022] [Accepted: 10/27/2022] [Indexed: 08/08/2023]
Abstract
BACKGROUND Drug resistance testing in HIV-1 low-level viremia (LLV) samples is challenging yet critical. Our study is aimed at assessing the performance of lentivirus concentration reagent (LCR) in combination with a validated Sanger sequencing (SS) for monitoring drug resistance mutations (DRMs) in LLV samples. METHODS A series of clinical samples were diluted and amplified for genotypic resistance testing (GRT) to prove the performance of the LCR. The Stanford HIV-1 drug resistance database (HIVdb version 8.9) was used to analyze the mutations. HIV-1 subtypes and CRFs were determined using the COMET online tool. The overall success rate of genotyping was compared with ultracentrifugation combined with SS. Furthermore, the success rates at varied VL of the two concentration methods were evaluated, and the DRMs of diluted samples were compared with those undiluted samples. RESULTS When LCR was used, the overall success rate was 90% (72/80) in the PR and RT regions and 60% (48/80) in the IN region. In addition, when HIV RNA was 1000 copies/ml, 400 copies/ml, 200 copies/ml, and 100 copies/ml, the success rates of PR and RT regions were 100%, 100%, 95%, and 65%, respectively, while the success rates of IN region were 85%, 60%, 45%, and 50%, respectively. We found that the sample DR-387A2 missed the E138A mutation, and mutations in other samples were consistent with undiluted samples using LCR. CONCLUSIONS LCR will support monitoring DRMs in HIV-1 patients with LLV and can be an effective alternative for small- and medium-sized laboratories that cannot afford an ultracentrifuge.
Collapse
Affiliation(s)
- Qun Li
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Fengting Yu
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Chuan Song
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
- Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - Hongxin Zhao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Liting Yan
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Qing Xiao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Xiaojie Lao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Siyuan Yang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Yunxia Tang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Jiang Xiao
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| | - Fujie Zhang
- Beijing Ditan Hospital, Capital Medical University, Beijing, China
- Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China
| |
Collapse
|
9
|
CRF07_BC is associated with slow HIV disease progression in Chinese patients. Sci Rep 2022; 12:3773. [PMID: 35260599 PMCID: PMC8904811 DOI: 10.1038/s41598-022-07518-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 02/21/2022] [Indexed: 11/09/2022] Open
Abstract
HIV subtypes convey important epidemiological information and possibly influence the rate of disease progression. In this study, HIV disease progression in patients infected with CRF01_AE, CRF07_BC, and subtype B was compared in the largest HIV molecular epidemiology study ever done in China. A national data set of HIV pol sequences was assembled by pooling sequences from public databases and the Beijing HIV laboratory network. Logistic regression was used to assess factors associated with the risk of AIDS at diagnosis ([AIDSAD], defined as a CD4 count < 200 cells/µL) in patients with HIV subtype B, CRF01_AE, and CRF07_BC. Of the 20,663 sequences, 9,156 (44.3%) were CRF01_AE. CRF07_BC was responsible for 28.3% of infections, followed by B (13.9%). In multivariable analysis, the risk of AIDSAD differed significantly according to HIV subtype (OR for CRF07_BC vs. B: 0.46, 95% CI 0.39─0.53), age (OR for ≥ 65 years vs. < 18 years: 4.3 95% CI 1.81─11.8), and transmission risk groups (OR for men who have sex with men vs. heterosexuals: 0.67 95% CI 0.6─0.75). These findings suggest that HIV diversity in China is constantly evolving and gaining in complexity. CRF07_BC is less pathogenic than subtype B, while CRF01_AE is as pathogenic as B.
Collapse
|
10
|
Li R, Song C, Chen D, Li C, Hao Y, Zeng H, Han J, Zhao H. Prevalence of Transmitted Drug Resistance among ART-Naïve HIV-Infected Individuals, Beijing, 2015-2018. J Glob Antimicrob Resist 2022; 28:241-248. [DOI: 10.1016/j.jgar.2022.01.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 12/02/2021] [Accepted: 01/20/2022] [Indexed: 11/16/2022] Open
|
11
|
Lan Y, Li L, He X, Hu F, Deng X, Cai W, Li J, Ling X, Fan Q, Cai X, Li L, Li F, Tang X. Transmitted drug resistance and transmission clusters among HIV-1 treatment-naïve patients in Guangdong, China: a cross-sectional study. Virol J 2021; 18:181. [PMID: 34488793 PMCID: PMC8422730 DOI: 10.1186/s12985-021-01653-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Accepted: 08/29/2021] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Transmitted drug resistance (TDR) that affects the effectiveness of the first-line antiretroviral therapy (ART) regimen is becoming prevalent worldwide. However, its prevalence and transmission among HIV-1 treatment-naïve patients in Guangdong, China are rarely reported. We aimed to comprehensively analyze the prevalence of TDR and the transmission clusters of HIV-1 infected persons before ART in Guangdong. METHODS The HIV-1 treatment-naïve patients were recruited between January 2018 and December 2018. The HIV-1 pol region was amplified by reverse transcriptional PCR and sequenced by sanger sequencing. Genotypes, surveillance drug resistance mutations (SDRMs) and TDR were analyzed. Genetic transmission clusters among patients were identified by pairwise Tamura-Nei 93 genetic distance, with a threshold of 0.015. RESULTS A total of 2368 (97.17%) HIV-1 pol sequences were successfully amplified and sequenced from the enrolled 2437 patients. CRF07_BC (35.90%, 850/2368), CRF01_AE (35.56%, 842/2368) and CRF55_01B (10.30%, 244/2368) were the main HIV-1 genotypes circulating in Guangdong. Twenty-one SDRMs were identified among fifty-two drug-resistant sequences. The overall prevalence of TDR was 2.20% (52/2368). Among the 2368 patients who underwent sequencing, 8 (0.34%) had TDR to protease inhibitors (PIs), 22 (0.93%) to nucleoside reverse transcriptase inhibitors (NRTIs), and 23 (0.97%) to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Two (0.08%) sequences showed dual-class resistance to both NRTIs and NNRTIs, and no sequences showed triple-class resistance. A total of 1066 (45.02%) sequences were segregated into 194 clusters, ranging from 2 to 414 sequences. In total, 15 (28.85%) of patients with TDR were included in 9 clusters; one cluster contained two TDR sequences with the K103N mutation was observed. CONCLUSIONS There is high HIV-1 genetic heterogeneity among patients in Guangdong. Although the overall prevalence of TDR is low, it is still necessary to remain vigilant regarding some important SDRMs.
Collapse
Affiliation(s)
- Yun Lan
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Linghua Li
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Xiang He
- Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, 160 Qunxian Road, Panyu District, Guangzhou, 511430, China
| | - Fengyu Hu
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Xizi Deng
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Weiping Cai
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Junbin Li
- Guangdong Center for Diagnosis and Treatment of AIDS, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Xuemei Ling
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China.,Guangdong Center for Diagnosis and Treatment of AIDS, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Qinghong Fan
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Xiaoli Cai
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Liya Li
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China
| | - Feng Li
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China.
| | - Xiaoping Tang
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, 627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China.
| |
Collapse
|